Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer

PURPOSE: The purpose of this study is to retrospectively compare the efficacy and tolerability between three regimens for first-line chemotherapy—gemcitabine plus capecitabine (GEM-X), gemcitabine plus erlotinib (GEM-T), and gemcitabine monotherapy (GEM)—in patients with advanced pancreatic cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Jae Yun, Cho, Jang Ho, Lee, Se Joon, Lee, Dong Ki, Yoon, Dong Sup, Cho, Jae Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398119/
https://www.ncbi.nlm.nih.gov/pubmed/25327494
http://dx.doi.org/10.4143/crt.2013.158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398119/
https://www.ncbi.nlm.nih.gov/pubmed/25327494
http://dx.doi.org/10.4143/crt.2013.158

Ejemplares similares